Ryan Sullivan is an Associate Professor of Medicine at Harvard Medical School and the Associate Director of the Melanoma Program and a member of the Termeer Center for Targeted Therapy at Mass General Cancer Center. Dr. Sullivan is an active clinical and translational investigator whose main areas of interest are the development of novel molecular targeted and immunotherapeutic combinations for malignant melanoma and other solid tumors. More recently, he has been interested in describing, predicting, and optimally treating immune related adverse events from immune checkpoint inhibition. Finally, Dr. Sullivan is active in the Society of Immunotherapy in Cancer (SITC) and serves as the Chair of the SITC Policy and anti-PD-1 resistance committees, as well as the Chair of the Melanoma Subcommittee.